Cargando…

Investigating the Retained Inhibitory Effect of Cobimetinib against p.P124L Mutated MEK1: A Combined Liquid Biopsy and in Silico Approach

SIMPLE SUMMARY: This work focuses on the peculiar contribution made by molecular dynamics simulation and in silico tools, in the choice of an effective second line therapy for a BRAF-mutated melanoma patient who developed resistance to the undergoing targeted therapy with BRAF/MEK inhibitors. Among...

Descripción completa

Detalles Bibliográficos
Autores principales: Catoni, Cristina, Poggiana, Cristina, Facchinetti, Antonella, Pigozzo, Jacopo, Piccin, Luisa, Chiarion-Sileni, Vanna, Rosato, Antonio, Minervini, Giovanni, Scaini, Maria Chiara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9454486/
https://www.ncbi.nlm.nih.gov/pubmed/36077693
http://dx.doi.org/10.3390/cancers14174153
_version_ 1784785358534213632
author Catoni, Cristina
Poggiana, Cristina
Facchinetti, Antonella
Pigozzo, Jacopo
Piccin, Luisa
Chiarion-Sileni, Vanna
Rosato, Antonio
Minervini, Giovanni
Scaini, Maria Chiara
author_facet Catoni, Cristina
Poggiana, Cristina
Facchinetti, Antonella
Pigozzo, Jacopo
Piccin, Luisa
Chiarion-Sileni, Vanna
Rosato, Antonio
Minervini, Giovanni
Scaini, Maria Chiara
author_sort Catoni, Cristina
collection PubMed
description SIMPLE SUMMARY: This work focuses on the peculiar contribution made by molecular dynamics simulation and in silico tools, in the choice of an effective second line therapy for a BRAF-mutated melanoma patient who developed resistance to the undergoing targeted therapy with BRAF/MEK inhibitors. Among the MEK inhibitors, we identified a drug alternative to trametinib, able to block the target even in the presence of a damaging mutation, and supported these findings, gathered by an in silico approach, with a liquid biopsy tracking of the response to treatment. The evolution of the disease, before and after the therapy change, was followed by analysis of the circulating tumor DNA and circulating melanoma cells. ABSTRACT: The systemic treatment of metastatic melanoma has radically changed, due to an improvement in the understanding of its genetic landscape and the advent of targeted therapy. However, the response to BRAF/MEK inhibitors is transitory, and big efforts were made to identify the mechanisms underlying the resistance. We exploited a combined approach, encompassing liquid biopsy analysis and molecular dynamics simulation, for tracking tumor evolution, and in parallel defining the best treatment option. The samples at different time points were collected from a BRAF-mutant melanoma patient who developed an early resistance to dabrafenib/trametinib. The analysis of the circulating tumor DNA (ctDNA) identified the MEK1 p.P124L mutation that confers resistance to trametinib. With an in silico modeling, we identified cobimetinib as an alternative MEK inhibitor, and consequently suggested a therapy switch to vemurafenib/cobimetinib. The patient response was followed by ctDNA tracking and circulating melanoma cell (CMC) count. The cobimetinib administration led to an important reduction in the BRAF p.V600E and MEK1 p.P124L allele fractions and in the CMC number, features suggestive of a putative response. In summary, this study emphasizes the usefulness of a liquid biopsy-based approach combined with in silico simulation, to track real-time tumor evolution while assessing the best treatment option.
format Online
Article
Text
id pubmed-9454486
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94544862022-09-09 Investigating the Retained Inhibitory Effect of Cobimetinib against p.P124L Mutated MEK1: A Combined Liquid Biopsy and in Silico Approach Catoni, Cristina Poggiana, Cristina Facchinetti, Antonella Pigozzo, Jacopo Piccin, Luisa Chiarion-Sileni, Vanna Rosato, Antonio Minervini, Giovanni Scaini, Maria Chiara Cancers (Basel) Communication SIMPLE SUMMARY: This work focuses on the peculiar contribution made by molecular dynamics simulation and in silico tools, in the choice of an effective second line therapy for a BRAF-mutated melanoma patient who developed resistance to the undergoing targeted therapy with BRAF/MEK inhibitors. Among the MEK inhibitors, we identified a drug alternative to trametinib, able to block the target even in the presence of a damaging mutation, and supported these findings, gathered by an in silico approach, with a liquid biopsy tracking of the response to treatment. The evolution of the disease, before and after the therapy change, was followed by analysis of the circulating tumor DNA and circulating melanoma cells. ABSTRACT: The systemic treatment of metastatic melanoma has radically changed, due to an improvement in the understanding of its genetic landscape and the advent of targeted therapy. However, the response to BRAF/MEK inhibitors is transitory, and big efforts were made to identify the mechanisms underlying the resistance. We exploited a combined approach, encompassing liquid biopsy analysis and molecular dynamics simulation, for tracking tumor evolution, and in parallel defining the best treatment option. The samples at different time points were collected from a BRAF-mutant melanoma patient who developed an early resistance to dabrafenib/trametinib. The analysis of the circulating tumor DNA (ctDNA) identified the MEK1 p.P124L mutation that confers resistance to trametinib. With an in silico modeling, we identified cobimetinib as an alternative MEK inhibitor, and consequently suggested a therapy switch to vemurafenib/cobimetinib. The patient response was followed by ctDNA tracking and circulating melanoma cell (CMC) count. The cobimetinib administration led to an important reduction in the BRAF p.V600E and MEK1 p.P124L allele fractions and in the CMC number, features suggestive of a putative response. In summary, this study emphasizes the usefulness of a liquid biopsy-based approach combined with in silico simulation, to track real-time tumor evolution while assessing the best treatment option. MDPI 2022-08-27 /pmc/articles/PMC9454486/ /pubmed/36077693 http://dx.doi.org/10.3390/cancers14174153 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
Catoni, Cristina
Poggiana, Cristina
Facchinetti, Antonella
Pigozzo, Jacopo
Piccin, Luisa
Chiarion-Sileni, Vanna
Rosato, Antonio
Minervini, Giovanni
Scaini, Maria Chiara
Investigating the Retained Inhibitory Effect of Cobimetinib against p.P124L Mutated MEK1: A Combined Liquid Biopsy and in Silico Approach
title Investigating the Retained Inhibitory Effect of Cobimetinib against p.P124L Mutated MEK1: A Combined Liquid Biopsy and in Silico Approach
title_full Investigating the Retained Inhibitory Effect of Cobimetinib against p.P124L Mutated MEK1: A Combined Liquid Biopsy and in Silico Approach
title_fullStr Investigating the Retained Inhibitory Effect of Cobimetinib against p.P124L Mutated MEK1: A Combined Liquid Biopsy and in Silico Approach
title_full_unstemmed Investigating the Retained Inhibitory Effect of Cobimetinib against p.P124L Mutated MEK1: A Combined Liquid Biopsy and in Silico Approach
title_short Investigating the Retained Inhibitory Effect of Cobimetinib against p.P124L Mutated MEK1: A Combined Liquid Biopsy and in Silico Approach
title_sort investigating the retained inhibitory effect of cobimetinib against p.p124l mutated mek1: a combined liquid biopsy and in silico approach
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9454486/
https://www.ncbi.nlm.nih.gov/pubmed/36077693
http://dx.doi.org/10.3390/cancers14174153
work_keys_str_mv AT catonicristina investigatingtheretainedinhibitoryeffectofcobimetinibagainstpp124lmutatedmek1acombinedliquidbiopsyandinsilicoapproach
AT poggianacristina investigatingtheretainedinhibitoryeffectofcobimetinibagainstpp124lmutatedmek1acombinedliquidbiopsyandinsilicoapproach
AT facchinettiantonella investigatingtheretainedinhibitoryeffectofcobimetinibagainstpp124lmutatedmek1acombinedliquidbiopsyandinsilicoapproach
AT pigozzojacopo investigatingtheretainedinhibitoryeffectofcobimetinibagainstpp124lmutatedmek1acombinedliquidbiopsyandinsilicoapproach
AT piccinluisa investigatingtheretainedinhibitoryeffectofcobimetinibagainstpp124lmutatedmek1acombinedliquidbiopsyandinsilicoapproach
AT chiarionsilenivanna investigatingtheretainedinhibitoryeffectofcobimetinibagainstpp124lmutatedmek1acombinedliquidbiopsyandinsilicoapproach
AT rosatoantonio investigatingtheretainedinhibitoryeffectofcobimetinibagainstpp124lmutatedmek1acombinedliquidbiopsyandinsilicoapproach
AT minervinigiovanni investigatingtheretainedinhibitoryeffectofcobimetinibagainstpp124lmutatedmek1acombinedliquidbiopsyandinsilicoapproach
AT scainimariachiara investigatingtheretainedinhibitoryeffectofcobimetinibagainstpp124lmutatedmek1acombinedliquidbiopsyandinsilicoapproach